Navigation Links
Analysis of Longer-Term Clinical Study Suggests Psychiatric Hospitalization Rates Decreased in Adults with Schizophrenia Treated With INVEGA® SUSTENNA®
Date:11/19/2010

se these problems could mean you're having a heart rhythm abnormality, contact your doctor IMMEDIATELY if you feel faint or feel a change in the way that your heart beats (palpitations).

High blood sugar and diabetes have been reported with INVEGA® SUSTENNA® and similar medicines. If you already have diabetes or have risk factors such as being overweight or a family history of diabetes, blood sugar testing should be done at the beginning and during the treatment. The complications of diabetes can be serious and even life-threatening. Call your doctor if you develop signs of high blood sugar or diabetes, such as being thirsty all the time, having to urinate or "pass urine" more often than usual, or feeling weak or hungry.

Weight gain has been observed with INVEGA® SUSTENNA® and other atypical antipsychotic medications. If you notice that you are gaining weight, please notify your doctor.

Some people may feel faint, dizzy, or may pass out when they stand up or sit up suddenly. Be careful not to get up too quickly. It may help if you get up slowly and sit on the edge of the bed or chair for a few minutes before you stand up. These symptoms may decrease or go away after your body becomes used to the medicine.

INVEGA® SUSTENNA® and similar medicines have been associated with decreases in the counts of white cells in circulating blood. If you have a history of low white blood cell counts or have unexplained fever or infection, then please contact your doctor right away.

INVEGA® SUSTENNA® and similar medicines can raise the blood levels of a hormone called prolactin and blood levels of prolactin remain high with continued use. This may result in some side effects including missed menstrual periods, leakage of milk from the breasts, development of breasts in men, or problems with erection.

If you have a prolonged or painful erection lasting more than 4 hours, seek immediate medical help
'/>"/>

SOURCE Ortho-McNeil Janssen Scientific Affairs, L.L.C.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... YORK , Sept. 2, 2015 Relmada ... novel therapies for the treatment of chronic pain, announced ... meetings at both the FBR Second Annual Healthcare Conference ... as follows: FBR Second Annual Healthcare Conference ... Boston No presentation, investor ...
(Date:9/2/2015)... Tumultuous market conditions – including changes in ... activity – have led more than half of today,s ... reps. This marks the first time that the number ... point, according to the spring 2015 AccessMonitor™ report ... . AccessMonitor™ aggregates sales-call records ...
(Date:9/2/2015)... Columbia and MENLO PARK, ... DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and ... development and commercialization of new cancer therapies, today ... "A Comparison of the Mechanisms and Cytotoxic ... Tumor Models Harboring Wild-type and Mutant p53," ...
Breaking Medicine Technology:Relmada Therapeutics to Participate in Two Upcoming Investor Conferences 2Crossing the threshold: More than half of physicians restrict access to sales reps 2Crossing the threshold: More than half of physicians restrict access to sales reps 3Crossing the threshold: More than half of physicians restrict access to sales reps 4Crossing the threshold: More than half of physicians restrict access to sales reps 5DelMar Pharmaceuticals Announces Expansion of VAL-083 Development Program to Include Ovarian Cancer 2DelMar Pharmaceuticals Announces Expansion of VAL-083 Development Program to Include Ovarian Cancer 3DelMar Pharmaceuticals Announces Expansion of VAL-083 Development Program to Include Ovarian Cancer 4
...  A dynamic and competitive medical device marketplace makes ... effective marketing group. However, creating and maintaining an ... due to a stringent regulatory environment and competitive ... their own internal effectiveness and efficiency to remain ...
... 16, 2012  The " Medical Equipment Design " online ... GlobalSpec drew more than 1,100 participants, with 80 percent ... organizations. The free virtual conference is now available ... easy access to educational presentations and industry-leading supplier resources ...
Cached Medicine Technology:Medical Device Study Delivers Marketing Budget and Staffing Metrics to Promote Efficient Use of Resources 2GlobalSpec Medical Equipment Design Online Trade Show and Event Draws More Than 1,100 Attendees 2GlobalSpec Medical Equipment Design Online Trade Show and Event Draws More Than 1,100 Attendees 3GlobalSpec Medical Equipment Design Online Trade Show and Event Draws More Than 1,100 Attendees 4
(Date:9/2/2015)... ... September 02, 2015 , ... ... the upper extremity surgical market, announced today that more than 600 successful patient ... in the hand. Plus, nearly 70 of these procedures have been on ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... content, records and case management solutions and services to both government and commercial ... Re-sizing and Image Clean-up utility for IBM’s Datacap document capture platform. EDAC ...
(Date:9/2/2015)... ... September 02, 2015 , ... On September 9, 2015, over 27,000 people ... the largest single-company convention to date for the state of Utah. , “We are ... tremendous event,” states David Stirling, doTERRA CEO. “One of the most exciting elements of ...
(Date:9/2/2015)... ... ... G-Hold ” was featured on NewsWatch as part of its monthly Tech Report, which ... expert and special reporter for NewsWatch, conducted the review and shared with viewers how ... likelihood of it dropping. , Tablets like the iPad and Samsung Galaxy Tab have ...
(Date:9/2/2015)... ... 02, 2015 , ... The payroll conference theme this year ... education covering legislative updates, including unemployment, global payroll best practices, and the latest ... Ultimate Software, the American Payroll Association, Barnett Associates, and the IRS, will keep ...
Breaking Medicine News(10 mins):Health News:Trigger Tome Surpasses 600 Successful Patient Procedures 2Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 2Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 3Health News:doTERRA to Host the Largest Single-Company Convention in the State of Utah 2Health News:Comfortably Hold a Tablet with G-Hold Hands Free Tablet Holder 2Health News:23rd Annual NJ Statewide Payroll Conference in Vernon, NJ at the Minerals Hotel on October 15-16, 2015 2
... women,s risk gets even smaller 10 years after stopping ... News) -- Women taking oral contraceptives are at a ... decade after stopping the pill even this very small ... that finding doesn,t change the recommendation for women to ...
... year over year growth driven by Loestrin 24 and Taclonex; Company ... updates full year 2007 financial guidance, ST. ... today announced its results for the quarter ended,September 30, 2007. Revenue ... of 16.3%, over the prior year quarter. The,primary drivers of the ...
... Highlighted by Continued Momentum in Global Commercialization, Program for Once-Daily ... ... III Study -, LAVAL, QC, Nov. 9 /PRNewswire-FirstCall/ - ... the third quarter of fiscal,2007, ended September 30, 2007. All ...
... event in 2007, net loss stable ... otherwise noted), BELLEVILLE, ON, Nov. 9 /PRNewswire-FirstCall/ - ... company, today announced financial results for the first,quarter of ... "We are also focused on the successful completion of ...
... Pharmaceutical product teams,have the power to make ... The problem is,launch teams often lack the right ... only produce a sub-optimal launch. In fact, ... and cross-functional team work are key ingredients,during product ...
... Support Continued Advancement of Novel Technology and ... ... Inc., a,privately-held therapeutic antibody product company, today announced that,it has raised ... A/S.,Additional investors participating significantly in the round were Frazier,Healthcare Ventures and ...
Cached Medicine News:Health News:Pill Poses Little Cervical Cancer Risk 2Health News:Pill Poses Little Cervical Cancer Risk 3Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 2Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 3Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 4Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 5Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 6Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 7Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 8Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 9Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 10Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 11Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 12Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 13Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 14Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 15Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 16Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 17Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 18Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 19Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 20Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 21Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 2Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 3Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 4Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 5Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 6Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 7Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 8Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 9Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 10Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 11Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 12Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 13Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 14
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: